Skip to main content
SpringerLink
Log in

New Concepts in Botulinum Toxin Therapy

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Duchen LW. Histologic differences between soleus and gastrocnemius muscles in the mouse after local injection of botulinum toxin. J Physiol (Lond) 1969; 204: 17–8

    Google Scholar 

  2. Duchen LW. Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of mouse: Differences between fast and slow muscles. J Neurol Neurosurg Psychiatry 1970; 33: 40–54

    Article  PubMed  CAS  Google Scholar 

  3. Borodic GE, Cozzolino D. Blepharospasm and its treatment with emphasis on botulinum toxin. Plast Reconstr Surg 1989; 83: 546–54

    Article  PubMed  CAS  Google Scholar 

  4. Scott AB, Kennedy RA, Stubbs AA. Botulinum A toxin for the treatment of blepharospasm. Arch Ophthalmol 1984; 102: 1464–8

    Article  Google Scholar 

  5. Borodic GE, Pearce LB, Ferrante RJ, et al. Pharmacology and histology of therapeutic botulinum toxin injections. In: Jankovic J, Hallet M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994

    Google Scholar 

  6. Borodic GE, Pearce, Ferrante RJ. Therapeutic botulinum toxin and diffusion properties. In: Das Gupta BR, editor. Botulinum and tetanus neurotoxins. New York: Plenum Press, 1993

    Google Scholar 

  7. Scott AB. Botulinum toxin injections to eye muscles to correct strabismus. J Am Ophthalmol Soc 1981; 79: 734–70

    CAS  Google Scholar 

  8. Jankovic J, Ford J. Blepharospasm and oro-facial dystonia. Pharmacologic findings in 100 patients. Ann Neurol 1979; 36: 635

    Article  Google Scholar 

  9. Frueh BR, Nelson CC, Kapustiak JF, et al. The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. Am J Ophthalmol 1988; 106: 45–7

    Article  PubMed  CAS  Google Scholar 

  10. Borodic GE, Pearce LB, Joseph M. Cranial cervical dystonias, multiple vs single injections strategies. A clinical study. Head Neck 1992; 14(1): 33–7

    Article  PubMed  CAS  Google Scholar 

  11. Jankovic J, Orman J. Botulinum toxin for cranial cervical dystonia: a double blind placebo controlled study. Neurology 1987; 37: 616–23

    Article  PubMed  CAS  Google Scholar 

  12. Gelb DJ, Lowenstein DH, Arminoff MJ. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 1989; 39: 80–4

    Article  PubMed  CAS  Google Scholar 

  13. Borodic GE, Mills L, Joseph M. Botulinum A toxin for the treatment of adult-onset spasmodic torticollis. Plast Reconst Surg 1991: 87: 285–9

    Article  PubMed  CAS  Google Scholar 

  14. Borodic GE, Joseph M, Fay L, et al. Botulinum A toxin for the treatment of spasmodic torticollis, dysphagia and regional toxin spread. Head Neck 1990; 12: 392–8

    Article  PubMed  CAS  Google Scholar 

  15. Ludlow CL. Treatment of speech and voice disorders with botulinum toxin. JAMA 1990; 264: 2671–5

    Article  PubMed  CAS  Google Scholar 

  16. Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol 1990; 28: 512–5

    Article  PubMed  CAS  Google Scholar 

  17. Roman LA, Mooney JF, Smith B, et al. Management of cerebral palsy with botulinum A toxin: preliminary investigation. J Pediatr Orthop 1993; 13: 489–95

    Article  Google Scholar 

  18. Blitzer A, Brin MF, Greene PE, et al. Botulinum toxin injection for the treatment of otomandibular dystonia. Ann Otol Rhinol Largyngol 1989: 98: 93–7

    CAS  Google Scholar 

  19. Acquadro M, Borodic GE. Treatment of myofascial pain with botulinum A toxin. Anesthesiology 1994; 80: 705–6

    Article  PubMed  CAS  Google Scholar 

  20. Hallen RI, Williams NS, Melling J, et al. Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 1988; 2: 7147

    Google Scholar 

  21. Jankovic J, Brin M. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 1194

    Google Scholar 

  22. Borodic GE, Ferrante R, Pearce LB, et al. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994; 9: 31–9

    Article  PubMed  CAS  Google Scholar 

  23. Borodic GE. Botulinum A toxin application for expressionistic ptosis overcorrection after frontalis sling procedures. Ophthal Plast Reconstr Surg 1992; 8: 137–42

    Article  PubMed  CAS  Google Scholar 

  24. Borodic GE, Weigner A, Ferrante R, et al. Orbicularis oculi innervation zone and implications for botulinum A toxin therapy for blepharospasm. Ophthal Plast Reconstr Surg 1991; 7: 5459

    Article  Google Scholar 

  25. Peowe W, Kleedorfer B, Wagner M, et al. Treatment of spasmodic torticollis with local injections of botulinum toxin: Clinical and electromyographic observations. New Trends Clin Neuropharmacol 1989; 3: 71

    Google Scholar 

  26. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988; 3: 333–5

    Article  PubMed  CAS  Google Scholar 

  27. Borodic GE, Ferrante R. Histologic effects of repeated botulinum toxin over many years in human orbicularis oculi muscle. J Clin Neuro Ophthal 1992; 12: 121–7

    Article  CAS  Google Scholar 

  28. Borodic GE, Pearce LB, Ferrante R. Circulating neutralizing antibodies after periocular injections of botulinum A toxin for blepharospasm [abstract]. Ophthalmic Plastic and Reconstructive Surgery Symposium; 1993 Nov 7: Chicago. In: Jankovic J, Hallet M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994

    Google Scholar 

  29. Hathaway C, Dang C. Immunology of clostridial neurotoxins. In: Jankovic J, Hallet M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994

    Google Scholar 

  30. Borodic GE, Pearce LB, Smith K, et al. Botulinum B toxin as an alternative to botulinum A toxin: a histologic study. Ophthal Plast Reconstr Surg 1993; 9: 182–90

    Article  PubMed  CAS  Google Scholar 

  31. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbiological neurotoxins in medicine. Microbiol Rev 1992; 50: 80–99

    Google Scholar 

  32. Clarke CE. Therapeutic potential of botulinum toxin in neurologic disorders. Q J Med 1992; 299: 197–205

    Google Scholar 

  33. Hambleton P, Cohen HE, Palmer BJ, et al. Antitoxins and botulinum toxin treatment. BMJ 1992; 304: 959–60

    Article  PubMed  CAS  Google Scholar 

  34. Quinn N, Hallet M. Dose standardization of botulinum toxin. Lancet 1989; 1: 964

    Article  PubMed  CAS  Google Scholar 

  35. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med 1993; 86: 493–4

    PubMed  CAS  Google Scholar 

  36. Marsden CD. Botulinum toxin: dangerous terminology errors [correspondence]. J R Soc Med 1993; 86: 494

    Google Scholar 

  37. Green PE, Fahn S. Use of botulinum type F injections to treat torticollis in patients with immunity to botulinun toxin type A. Mov Disord 1993; 8: 479–83

    Article  Google Scholar 

  38. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993; 365: 160–3

    Article  PubMed  CAS  Google Scholar 

  39. Sellin LC, Thesleff S, DasGupta BR. Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction. Acta Physiol Scand 1983; 199: 127–33

    Article  Google Scholar 

  40. Pearce LB, Borodic GE, Johnson EA, et al. The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicon. In press

  41. Pearce LB, Borodic GE, MacCallum R, et al. A mystery resolved by the median paralysis unit (regional denervation unit). J R Soc Med. In press

  42. Borodic GE, Pearce LB, Goodnough M, et al. Myogenic rabbit ptosis model for bioactivity testing of botulinun toxin preparation. Presented at the Benign Essential Blepharospasm Research Foundation, University of Minnesota, 5 August, 1994

Download references

Author information

Authors and Affiliations

  1. Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, Massachusetts, USA

    Gary E. Borodic

  2. Department of Pharmacology, Boston University, Boston, Massachussetts, USA

    L. Bruce Pearce

Authors
  1. Gary E. Borodic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Bruce Pearce
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borodic, G.E., Pearce, L.B. New Concepts in Botulinum Toxin Therapy. Drug-Safety 11, 145–152 (1994). https://doi.org/10.2165/00002018-199411030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199411030-00001

Keywords

Search

Navigation